BNY Mellon High Yield Beta ETF (BKHY) NPORT-P BNY Mellon Innovators ETF (Nov 2023 report)

STATEMENT

OF

INVESTMENTS

November

30,

2023

(Unaudited)

1

Description

Shares

Value

($)

Common

Stocks

–

99.5%

Consumer

Discretionary

Distribution

&

Retail

–

0.5%

Chewy,

Inc.,

Class

A

(a)

2,969

51,720

Consumer

Durables

&

Apparel

–

5.7%

Garmin

Ltd.

981

119,918

Lululemon

Athletica,

Inc.

(a)

678

302,930

Peloton

Interactive,

Inc.,

Class

A

(a)

28,280

160,065

582,913

Consumer

Services

–

3.4%

Airbnb,

Inc.,

Class

A

(a)

1,398

176,623

DraftKings,

Inc.,

Class

A

(a)

4,416

168,868

345,491

Energy

–

3.2%

Cactus,

Inc.,

Class

A

7,721

328,065

Financial

Services

–

5.8%

Ares

Management

Corp.,

Class

A

3,034

340,566

Block,

Inc.

(a)

4,013

254,545

595,111

Food,

Beverage

&

Tobacco

–

3.9%

Celsius

Holdings,

Inc.

(a)

1,761

87,187

Freshpet,

Inc.

(a)

3,150

223,492

Vital

Farms,

Inc.

(a)

6,799

90,563

401,242

Health

Care

Equipment

&

Services

–

13.1%

Align

Technology,

Inc.

(a)

866

185,151

DexCom,

Inc.

(a)

3,080

355,802

Inspire

Medical

Systems,

Inc.

(a)

899

130,634

Intuitive

Surgical,

Inc.

(a)

655

203,600

iRhythm

Technologies,

Inc.

(a)

1,372

117,004

Outset

Medical,

Inc.

(a)

7,531

39,462

Privia

Health

Group,

Inc.

(a)

5,953

122,989

TransMedics

Group,

Inc.

(a)

2,484

187,989

1,342,631

Materials

–

1.1%

Albemarle

Corp.

971

117,753

Media

&

Entertainment

–

12.6%

Alphabet,

Inc.,

Class

C

(a)

4,155

556,437

Liberty

Media

Corp.-Liberty

Formula

One,

Class

C

(a)

2,727

173,601

Netflix,

Inc.

(a)

742

351,686

Trade

Desk,

Inc.

(The),

Class

A

(a)

3,052

215,044

1,296,768

Pharmaceuticals,

Biotechnology

&

Life

Sciences

–

23.3%

10X

Genomics,

Inc.,

Class

A

(a)

2,882

125,425

Alnylam

Pharmaceuticals,

Inc.

(a)

1,045

175,821

STATEMENT

OF

INVESTMENTS

(continued)

2

See

Notes

to

Statement

of

Investments

Description

Shares

Value

($)

Common

Stocks

–

99.5%

(continued)

Pharmaceuticals,

Biotechnology

&

Life

Sciences

–

23.3%

(continued)

Ascendis

Pharma

A/S,

ADR

(a)

2,229

223,858

BioMarin

Pharmaceutical,

Inc.

(a)

2,736

249,195

Crinetics

Pharmaceuticals,

Inc.

(a)

4,507

143,278

Cytokinetics,

Inc.

(a)

4,005

134,087

Denali

Therapeutics,

Inc.

(a)

5,092

94,304

Illumina,

Inc.

(a)

1,534

156,391

Insmed,

Inc.

(a)

10,879

272,193

Keros

Therapeutics,

Inc.

(a)

2,185

66,293

Pacific

Biosciences

of

California,

Inc.

(a)

11,878

100,725

Prothena

Corp.

PLC

(a)

1,993

64,932

Repligen

Corp.

(a)

1,319

207,413

Sarepta

Therapeutics,

Inc.

(a)

1,577

128,179

Twist

Bioscience

Corp.

(a)

7,778

187,061

Xenon

Pharmaceuticals,

Inc.

(a)

1,723

63,027

2,392,182

Real

Estate

Management

&

Development

–

4.1%

CoStar

Group,

Inc.

(a)

5,112

424,501

Semiconductors

&

Semiconductor

Equipment

–

7.6%

NVIDIA

Corp.

1,673

782,462

Software

&

Services

–

15.2%

DoubleVerify

Holdings,

Inc.

(a)

5,288

175,562

Dynatrace,

Inc.

(a)

4,290

229,729

MongoDB,

Inc.

(a)

536

222,837

Shopify,

Inc.,

Class

A

(a)

3,323

241,981

Snowflake,

Inc.,

Class

A

(a)

1,906

357,718

Twilio,

Inc.,

Class

A

(a)

5,256

339,958

1,567,785

Total

Common

Stocks

(cost

$9,909,831)

10,228,624

Investment

Companies

–

0.5%

Registered

Investment

Companies

–

0.5%

Dreyfus

Institutional

Preferred

Government

Money

Market

Fund,

Institutional

Shares,

5.32%

(b)(c)

(cost

$53,346)

53,346

53,346

Total

Investments

(cost

$9,963,177)

100.0%

10,281,970

Liabilities,

Less

Cash

and

Receivables

0.0%

(2,753)

Net

Assets

100.0%

10,279,217

ADR—American

Depositary

Receipt

(a)

Non-income

producing

security.

(b)

Investment

in

affiliated

issuer.

The

investment

objective

of

this

investment

company

is

publicly

available

and

can

be

found

within

the

investment

company’s

prospectus.

(c)

The

rate

shown

is

the

1-day

yield

as

of

November

30,

2023.

NOTES

TO

STATEMENT

OF

INVESTMENTS

(Unaudited)

3

The

Financial

Accounting

Standards

Board

(“FASB”)

Accounting

Standards

Codification

(“ASC”)

is

the

exclusive

reference

of

authoritative

U.S.

generally

accepted

accounting

principles

(“GAAP”)

recognized

by

the

FASB

to

be

applied

by

nongovernmental

entities.

Rules

and

interpretive

releases

of

the

Securities

and

Exchange

Commission

(“SEC”)

under

authority

of

federal

laws

are

also

sources

of

authoritative

GAAP

for

SEC

registrants. BNY

Mellon

Innovators

ETF (the

“fund”)

is an

investment

company

and

applies

the

accounting

and

reporting

guidance

of

the

FASB

ASC

Topic

946

Financial

Services-Investment

Companies. The

fund’s

financial

statements

are

prepared

in

accordance

with

GAAP,

which

may

require

the

use

of

management

estimates

and

assumptions.

Actual

results

could

differ

from

those

estimates.  

(a)

Portfolio

valuation:

The

fair

value

of

a

financial

instrument

is

the

amount

that

would

be

received

to

sell

an

asset

or

paid

to

transfer

a

liability

in

an

orderly

transaction

between

market

participants

at

the

measurement

date

(i.e.,

the

exit

price).

GAAP

establishes

a

fair

value

hierarchy

that

prioritizes

the

inputs

of

valuation

techniques

used

to

measure

fair

value.

This

hierarchy

gives

the

highest

priority

to

unadjusted

quoted

prices

in

active

markets

for

identical

assets

or

liabilities

(Level

1

measurements)

and

the

lowest

priority

to

unobservable

inputs

(Level

3

measurements).

Additionally,

GAAP

provides

guidance

on

determining

whether

the

volume

and

activity

in

a

market

has

decreased

significantly

and

whether

such

a

decrease

in

activity

results

in

transactions

that

are

not

orderly.

GAAP

requires

enhanced

disclosures

around

valuation

inputs

and

techniques

used

during

annual

and

interim

periods.

Various

inputs

are

used

in

determining

the

value

of

the

fund’s

investments

relating

to

fair

value

measurements.

These

inputs

are

summarized

in

the

three

broad

levels

listed

below:

Level

1

—

unadjusted

quoted

prices

in

active

markets

for

identical

investments.

Level

2

—

other

significant

observable

inputs

(including

quoted

prices

for

similar 

investments,

interest

rates,

prepayment

speeds,

credit

risk,

etc.).

Level

3

—

significant

unobservable

inputs

(including

the

fund’s

own

assumptions

in

determining

the

fair

value

of

investments).

The

inputs

or

methodology

used

for

valuing

securities

are

not

necessarily

an

indication

of

the

risk

associated

with

investing

in

those

securities.

Changes

in

valuation

techniques

may

result

in

transfers

in

or

out

of

an

assigned

level

within

the

disclosure

hierarchy.

Valuation

techniques

used

to

value

the

fund’s

investments

are

as

follows:

NOTES

TO

STATEMENT

OF

INVESTMENTS

(Unaudited)

(continued)

4

BNY

Mellon

ETF

Trust’s

(the

“Trust”) Board

of

Trustees

(the

“Board”)

has

designated

the

Adviser

as

the

fund’s

valuation

designee

to

make

all

fair

value

determinations

with

respect

to

the

fund’s

portfolio

of

investments,

subject

to

the

Board’s

oversight

and

pursuant

to

Rule

2a-5

under

the

Act.

Investments

in

equity

securities,

including

ETFs

(but

not

including

investments

in

other

open-end

registered

investment

companies),

generally

are

valued

at

the

last

sales

price

on

the

day

of

valuation

on

the

securities

exchange

or

national

securities

market

on

which

such

securities

primarily

are

traded.

Securities

listed

on

the

National

Association

of

Securities

Dealers

Automated

Quotation

System

(“NASDAQ”)

for

which

market

quotations

are

available

will

be

valued

at

the

official

closing

price.

If

there

are

no

transactions

in

a

security,

or

no

official

closing

prices

for

a

NASDAQ

market-listed

security

on

that

day,

the

security

will

be

valued

at

the

average

of

the

most

recent

bid

and

asked

prices.

Bid

price

is

used

when

no

asked

price

is

available.

Open

short

positions

for

which

there

is

no

sale

price

on

a

given

day

are

valued

at

the

lowest

asked

price.

Registered

investment

companies

that

are

not

traded

on

an

exchange

are

valued

at

their

net

asset

value.

All

of

the

preceding

securities

are

generally

categorized

within

Level

1

of

the

fair

value

hierarchy. 

When

market

quotations

or

official

closing

prices

are

not

readily

available,

or

are

determined

not

to

reflect

fair

value

accurately,

they are

valued

at

fair

value

as

determined

in

good

faith

based

on

procedures

approved

by

the

Board.

Fair

value

of

investments

may

be

determined

by

valuation

designee

using

such

information

as

it

deems

appropriate

under

the

circumstances.

Certain

factors

may

be

considered

when

fair

valuing

investments

such

as:

fundamental

analytical

data,

the

nature

and

duration

of

restrictions

on

disposition,

an

evaluation

of

the

forces

that

influence

the

market

in

which

the

securities

are

purchased

and

sold,

and

public

trading

in

similar

securities

of

the

issuer

or

comparable

issuers.

These

securities

are

either

categorized

within

Level

2

or

3

of

the

fair

value

hierarchy

depending

on

the

relevant

inputs

used.

For

securities

where

observable

inputs

are

limited,

assumptions

about

market

activity

and

risk

are

used

and

are

generally

categorized

within

Level

3

of

the

fair

value

hierarchy.

The

table

below

summarizes

the

inputs

used

as

of November

30,

2023

in

valuing

the

fund’s

investments:

5

Fair

Value

Measurements

Additional

investment

related

disclosures

are

hereby

incorporated

by

reference

to

the

semi-annual

report

previously

filed

with

the

SEC

on

Form

N-CSR.

At November

30,

2023,

accumulated

net

unrealized

appreciation on

investments

was

$318,793,

consisting

of

gross

appreciation

of

$1,436,998

and

gross

depreciation

of

$1,118,205.

At

November

30,

2023,

the

cost

of

investments

for

federal

income

tax

purposes

was

substantially

the

same

as

the

cost

for

financial

reporting

purposes

(see

the

Statement

of

Investments).

Level

1

-

Unadjusted

Quoted

Prices

Level

2

-

Other

Significant

Observable

Inputs

Level

3

-

Significant

Unobservable

Inputs

Total

Assets

($)

Investments

In

Securities:

†

Common

Stocks

10,228,624

—

—

10,228,624

Investment

Companies

53,346

—

—

53,346

†

See

Statement

of

Investments

for

additional

detailed

categorizations,

if

any.